What We Still Do Not Know About Vaping

What We Don’t Know About Vape? UK Guide 2026 | Dispergo Vaping
Consumer guide • Prefilled pod systems

What We Still
Do Not Know

Honest acknowledgment of remaining uncertainties. 20+ year effects. Flavour decades. Individual variation. Direction clear, magnitude uncertain. Full picture below.

Updated: April 2026
Written by: Josh Douglas, Dispergo CEO
For: Adult smokers & vapers (18+)
The short answer

Main remaining uncertainties: long-term effects over 20+ years (modern vape emerged 2007), specific flavour compound effects over decades of chronic inhalation, individual susceptibility variation, effects on developing brain over long-term use, very heavy chronic use patterns, specific product type long-term impact, genetic factors affecting response. However what we DO know: vape is substantially less harmful than smoking in short to medium term, no major vape-specific disease patterns have emerged in 15+ years, mechanism strongly supports expected continued lower harm than smoking. Uncertainty is about MAGNITUDE of benefit not DIRECTION of comparison. For current smokers this uncertainty is smaller factor than known smoking harm. For non-smokers uncertainty is appropriate reason not to start. Full cessation eliminates uncertainty entirely.

Three context facts

Why some uncertainty
remains about vape

Three facts covering the newness of modern vape, the available data horizon plus the key framing of uncertainty.

Since2007

Modern vape age

Modern vape emerged around 2007. 20+ year chronic data still developing over coming years.

15+ yearsdata exists

Medium-term evidence

Available data covers this horizon reliably. No major vape-specific disease patterns emerged.

Direction clearmagnitude uncertain

Key framing

We know vape is less harmful than smoking. How much less exactly still being established.

The detailed answer

Direction clear. Magnitude uncertain. Full cessation eliminates uncertainty.

Main remaining uncertainties about vape: long-term effects over 20+ years (modern vape emerged 2007), specific flavour compound effects over decades of chronic inhalation, individual susceptibility variation, effects on developing brain over long-term use, very heavy chronic use patterns, specific product types long-term impact, genetic factors affecting response. What we do know: vape is substantially less harmful than smoking in short to medium term, no major vape-specific disease patterns have emerged in 15+ years of use, mechanism supports expected continued lower harm than smoking. The uncertainty is about magnitude of benefit not direction of comparison. Here is the honest picture of what remains unknown plus how to navigate it. For what we do know see our honest harm guide. This article is general consumer information, not medical advice.

Why honesty about uncertainty matters. Pretending we know everything gives false confidence. Pretending we know nothing paralyses decision-making. UK evidence supports vape as harm reduction for smokers despite remaining uncertainties. Uncertainty magnitude matters for individual decisions but does not negate the direction of benefit for smokers.

The timeline context

Understanding why long-term uncertainty exists:

Modern vape is new.

  • Modern e-cigarettes emerged around 2007.
  • Mass adoption mainly post-2012.
  • UK TPD framework established 2016.
  • 15 years of significant use history.
  • 20+ year data requires users vaping that long.

Compared to smoking data.

  • Smoking causes documented for decades.
  • Major lung cancer smoking link established 1950s.
  • 70+ years of systematic study.
  • Multiple generations of chronic users studied.
  • Extensive decades-long data exists.

What this means.

  • Vape is in earlier phase of evidence accumulation.
  • Long-term uncertainty is normal for newer products.
  • Research fills gaps gradually.
  • Direction of evidence is clear; magnitude still being established.

Specific uncertainties: long-term effects

Decades-long chronic inhalation of PG plus VG.

  • Both safe for oral consumption plus short-term inhalation.
  • Chronic daily inhalation over 20-40 years not fully studied.
  • Possible cumulative respiratory effects uncertain.
  • Individual variation may matter over long timelines.

Flavour compound chronic effects.

  • UK TPD bans particularly concerning compounds (diacetyl, etc).
  • Remaining compounds individually meet food safety standards.
  • Chronic inhalation of specific compounds over decades less studied.
  • Interaction effects between compounds less understood.

Cardiovascular effects over decades.

  • Short-term cardiovascular effects of nicotine well-established.
  • Chronic 20+ year cardiovascular impact of vape nicotine less clear.
  • Expected much less than smoking but exact magnitude uncertain.

Cancer risk over long periods.

  • Most smoking carcinogens absent from vape.
  • Cancer typically develops over 20+ years of smoking.
  • Equivalent long-term vape cancer data still developing.
  • Current data shows much lower cancer risk than smoking.
  • Long-term magnitude of any vape cancer risk uncertain.

Respiratory disease over decades.

  • Smoking COPD emerges after 20+ years.
  • Vape-equivalent chronic respiratory disease patterns not established.
  • Current data suggests much lower respiratory harm than smoking.
  • Decades-long vape respiratory outcomes still emerging.

Specific uncertainties: individual variation

Genetic factors affecting response.

  • CYP2A6 variations affect nicotine metabolism.
  • Genetic factors in flavour compound sensitivity.
  • Individual immune response variation.
  • Genetic cardiovascular susceptibility variation.
  • Full individual risk prediction not possible.

Existing health conditions.

  • Interactions with specific conditions less studied.
  • Cancer survivors vape impact unclear.
  • Specific immune conditions response variable.
  • Chronic disease interaction complex.

Lifestyle factor interactions.

  • Alcohol plus vape combined effects.
  • Stress plus vape interactions.
  • Exercise plus vape cardiovascular effects.
  • Diet interactions uncertain.

Specific uncertainties: developmental effects

Developing brain long-term.

  • Brain develops into mid-20s.
  • Short-term effects on adolescent brain documented.
  • Long-term consequences of adolescent vape use still emerging.
  • Data on 10+ year use starting in teens accumulating.
  • Stronger lifetime dependence established but full cognitive outcomes uncertain.

Pregnancy plus foetal effects.

  • Nicotine effects on foetus established.
  • Vape-specific pregnancy outcomes still being characterised.
  • Long-term child development after maternal vape use uncertain.
  • NHS guidance: stop during pregnancy where possible reflects uncertainty.

Reproductive effects.

  • Some short-term fertility effects of nicotine documented.
  • Long-term reproductive outcomes of vape less studied.
  • Effects on children of long-term users before conception uncertain.

Specific uncertainties: heavy chronic use

Very heavy daily use.

  • Chain vaping all day over years not fully studied.
  • Cumulative exposure patterns uncertain for heaviest users.
  • May differ significantly from moderate use.

Multi-decade continuous use.

  • Users who have vaped heavily for 10-15 years provide initial data.
  • Users vaping for 30-40 years do not yet exist.
  • Full lifetime exposure impact requires such cohorts.

Dose accumulation.

  • Total lifetime nicotine exposure effects.
  • Total lifetime PG/VG inhalation effects.
  • Total lifetime flavour compound exposure.
  • Dose-response at highest exposures uncertain.

Specific uncertainties: product variation

Specific device types.

  • Pod systems vs sub-ohm vs disposables may have different profiles.
  • Temperature effects on vapour composition.
  • Coil material plus heating element effects.
  • Long-term differences between device types uncertain.

Specific flavour categories.

  • Fruit vs dessert vs menthol vs tobacco flavour compounds differ.
  • Long-term category-specific effects unclear.
  • Individual flavour ingredient decades-long effects uncertain.

Specific PG/VG ratios.

  • 50/50, 70/30, max VG produce different exposures.
  • Long-term ratio-specific outcomes less studied.
  • Individual preference effects on health uncertain.

Product quality variation.

  • UK TPD compliant vs non-compliant vastly different.
  • Quality differences within compliant products matter.
  • Black market products introduce major uncertainty.

What we DO know despite uncertainty

Uncertainty about specific long-term magnitudes does not negate established knowledge:

Vape is much less harmful than smoking.

  • Combustion products absent from vape are the main smoking harm drivers.
  • Mechanism strongly supports substantially less harm.
  • Available 15+ year data supports this.
  • PHE ~95% less harmful estimate remains reasonable.

Nicotine itself is moderately harmful.

  • Well-characterised physiological effects.
  • Not a carcinogen.
  • Cardiovascular effects established.
  • Addictive with clear mechanisms.

Vape short-term effects are modest.

  • Dry mouth, throat irritation in some users.
  • Possible asthma triggering.
  • Some cardiovascular effects.
  • Some mild inflammation.
  • Much less than smoking effects.

Ex-smoker switchers benefit.

  • Measurable health improvements on switching.
  • Cardiovascular, respiratory improvements documented.
  • Lower cancer risk than continued smoking.
  • NHS-supported harm reduction pathway.

No major vape-specific disease patterns in 15+ years.

  • Mass adoption since early 2010s.
  • No equivalent of smoking-caused COPD plus lung cancer emerging.
  • Active surveillance continues.
  • Reasonable inference that long-term vape will be much less harmful than smoking.

How to navigate uncertainty

For current smokers.

  • Smoking certainty of harm outweighs vape uncertainty.
  • Switching meaningful harm reduction despite some unknowns.
  • NHS supports this pathway.
  • Full cessation cleanest eventually.

For non-smokers.

  • Uncertainty is reason not to start.
  • No harm reduction benefit to offset unknowns.
  • Do not start vape.

For existing vapers.

  • Consider long-term step-down plans.
  • Full cessation eliminates uncertainty entirely.
  • Continue monitoring symptoms.
  • Stay informed as evidence develops.

For specific populations.

  • Pregnancy: stop where possible reflecting uncertainty.
  • Minors: do not vape; developmental uncertainties significant.
  • Health conditions: GP input to individual situation.
  • Cancer history: extra caution warranted.

The uncertainty trap

A common mistake: using uncertainty to justify harmful choices.

The pattern.

  • “We do not know everything about vape.”
  • “Therefore I might as well keep smoking.”
  • Wrong conclusion.

Why it fails.

  • Smoking certainty is of known harm.
  • Vape uncertainty is about how much safer.
  • These are different types of uncertainty.
  • Continuing smoking to avoid uncertainty accepts known harm.

Better framework.

  • Uncertainty about magnitude not direction.
  • Direction is clear: vape much less harmful.
  • Magnitude uncertainty doesn’t change the basic comparison.
  • Full cessation of all nicotine cleanest for complete certainty.

Research trajectory

What research is underway to fill gaps:

Longitudinal cohort studies.

  • Following same users over many years.
  • Documenting health outcomes as use accumulates.
  • Comparing with non-users plus ex-smokers.
  • Major studies in UK, US plus other countries.

Specific compound research.

  • Individual flavour compound safety studies.
  • PG plus VG chronic inhalation research.
  • Interaction studies between compounds.

Population surveillance.

  • NHS monitoring vape use outcomes.
  • OHID evidence reviews ongoing.
  • Cancer registries tracking.
  • Respiratory disease surveillance.

Specific population studies.

  • Youth vape outcomes.
  • Pregnancy outcomes.
  • Existing condition interactions.
  • Genetic susceptibility.

Over the next 10-20 years significant uncertainty will resolve. Some specific long-term questions may take longer.

Practical approach

  • Some uncertainty is real plus will remain for years.
  • Direction of evidence is clear: vape much less harmful than smoking.
  • Magnitude of benefit uncertain but substantial.
  • For smokers: uncertainty doesn't negate harm reduction case.
  • For non-smokers: uncertainty is reason not to start.
  • Full cessation eliminates uncertainty entirely.

For those navigating vape use with appropriate caution, our nicotine salts collection features UK TPD-compliant products with regulatory quality standards across every legal strength from 20mg down to 3mg.

UK research source check. This article reflects current state of evidence plus explicit uncertainty as assessed by UK institutions including OHID plus Royal College of Physicians. Ongoing research continues to refine the picture. For current state check nhs.uk plus gov.uk resources. This article is general consumer information not medical advice.
Five main uncertainty areas

Where research
continues

Five main areas where uncertainty remains. All being actively researched. None negate established direction of evidence.

20+ year effects

Modern vape emerged 2007. True decades-long chronic effects still accumulating. Research ongoing.

Flavour compound decades

UK TPD bans concerning compounds. Remaining ingredients long-term inhalation effects less studied.

Individual variation

Genetic, lifestyle plus condition interactions. Full risk prediction not yet possible.

Developmental effects

Adolescent brain plus pregnancy outcomes over long-term still being characterised.

Heavy chronic use

Very heavy daily use over 20-30 years not yet possible to study directly.

Four facts on vape uncertainty

How to think about
remaining unknowns

Direction clear, magnitude uncertain

We know vape much less harmful than smoking. Exactly how much less still being established.

15+ years of data exists

No major vape-specific disease patterns emerged. Modern vape history long enough for some confidence.

Smoking certainty vs vape uncertainty

Different types of uncertainty. Continuing smoking to avoid unknowns accepts known harm.

Full cessation removes uncertainty entirely

Cleanest option for those wanting complete certainty. NHS Stop Smoking Services support.

UK TPD regulatory framework reduces uncertainty

Shop the nicotine salts range

Our nicotine salts collection features UK TPD-compliant products. Banned substances excluded. Full ingredient disclosure. Every UK legal strength from 20mg down to 3mg. Free next-day delivery on orders over £20.

Handling uncertainty well vs poorly

What navigates uncertainty
vs what falls into traps

Specific approaches handle vape uncertainty well. Others fall into common traps. Here is the side by side for informed decision-making.

Navigates well

Good framework

  • For smokers: switching despite some uncertainty harm reduction substantial even with unknowns.
  • For non-smokers: not starting vape uncertainty appropriate reason to avoid.
  • Full cessation as eventual goal eliminates uncertainty entirely.
  • UK TPD-compliant products reduces uncertainty from banned compounds.
  • Staying informed via official UK sources nhs.uk, gov.uk for current evidence.
  • GP consultation for individual situations applies uncertainty to your specific case.
Falls into traps

Common mistakes

  • Continuing smoking because of vape uncertainty accepts known harm to avoid unknowns.
  • Dismissing uncertainty entirely real unknowns deserve consideration.
  • Starting vape as non-smoker despite uncertainty no benefit to offset risks.
  • Black market products adding avoidable uncertainty no regulatory quality.
  • Heavy chronic use ignoring ongoing research individual uncertainty compounds.
  • Treating uncertainty as reason to avoid any decision evidence-based action possible despite unknowns.

For the wider view on vape, research plus uncertainty questions, our full health hub covers every major question UK readers ask.

Part of the hub

Back to the Prefilled Pod Systems guide

This article is one chapter inside our complete Prefilled Pod Systems knowledge base. Head back to the hub for the full index covering refilling, safety, longevity plus regulation.

Keep reading

More on vape research

For the honest harm assessment including what we DO know, our piece on is vaping bad for you covers the seven established harm categories. For the long-term comparison with smoking specifically, is long term vaping safer than long term smoking walks through that horizon. And for UK institutional position reflecting current evidence, what Public Health England and the NHS say about vaping covers the official UK stance.

Frequently asked

Vape uncertainty questions

What do we still not know about vaping?
Main remaining uncertainties: long-term effects over 20+ years (modern vape emerged 2007), specific flavour compound effects over decades of inhalation, individual susceptibility variation, effects on developing brain over long-term use, very heavy chronic use patterns, specific product types long-term impact, genetic factors affecting response. What we do know: vape substantially less harmful than smoking short to medium term, no major vape-specific disease patterns emerged in 15+ years. Uncertainty is about magnitude of benefit not direction of comparison.
Why is there uncertainty about long-term vape effects?
Modern vape emerged around 2007. True long-term (20+ year) data requires users who have vaped that long which is only now becoming available. Current data covers 10-15 years reliably. Decades-long chronic inhalation effects of PG, VG plus flavour compounds not fully characterised. Individual variation means rare effects may not yet be apparent. Research continues to fill these gaps. This uncertainty is standard for any relatively new product plus does not mean vape is equivalent to smoking in harm.
Should uncertainty make me avoid switching from smoking?
No. Smoking certainty is of known harm (kills approximately half of long-term users). Vape uncertainty is about how much safer. Different types of uncertainty. Current evidence substantially supports vape as less harmful for smokers. Waiting for complete long-term certainty while continuing smoking means accepting known harm. NHS guidance: switching from smoking to vape is meaningful harm reduction even with some remaining uncertainty. Full cessation cleanest long-term position.
What research is happening on vape uncertainties?
Ongoing research includes: longitudinal cohort studies following long-term vapers, specific compound analysis including flavour ingredients, cardiovascular outcome studies, respiratory outcome tracking, cancer surveillance, youth plus pregnancy outcome research, individual susceptibility studies. UK OHID continues evidence reviews. International research ongoing. Data accumulates gradually as use patterns mature. Some uncertainties will resolve in coming years; others may take decades to fully address.
How do I think about vape uncertainty personally?
Practical framework: for non-smokers uncertainty is reason not to start (no harm reduction benefit to offset it). For current smokers uncertainty is smaller factor than known smoking harm. For existing vapers full cessation removes uncertainty entirely. For specific populations (pregnant, conditions) uncertainty is additional reason for caution plus GP consultation. Uncertainty is real but not reason to make no decision. Evidence-based direction of travel is clear even if magnitudes are uncertain.
When will we have full vape long-term data?
Progressive. 20-year data emerging over the next 5 years as early adopters reach that mark. 30-year data available after that. Lifetime use data requires full lifetime cohorts which takes decades. Significant uncertainty should resolve over next 10-15 years as research continues. Some specific long-term questions may take much longer. Available evidence is already substantial for basic harm reduction decisions.